canadian drug prices

Printer-friendly version
FDA approval may spell trouble for Canadian patients

In 2022, the United States accounted for 42.6 per cent of pharmaceutical sales worldwide compared to 2 per cent for Canada.

Printer-friendly version
Pandemic showed that Canada needs a thriving biopharmaceutical industry

Government policies and regulations have created an environment hostile to research and innovation.

Printer-friendly version
Proposed ‘drug price’ changes threaten access for Canadian patients

Advanced clinical trials in Canada, which were consistent between 2015 and 2019, decreased by 26 per cent in 2020.

Printer-friendly version
Ottawa’s changes to drug-pricing will deny some Canadians potentially lifesaving drugs

Forcing manufacturers of high-cost drugs to reduce their prices by up to 80 per cent is unsustainable.

Printer-friendly version
Colorado wants your drugs

If every U.S. prescription was filled in Canada, the annual Canadian drug supply would be exhausted in 52 days.

Printer-friendly version
Liberal pharmacare fantasy raises more questions than answers

The latest federal budget revealed the Trudeau government’s plan to move forward on national pharmacare.

Printer-friendly version

In January, GlaxoSmithKline, a global pharmaceutical manufacturer, announced that it would stop delivering its prescription drugs to wholesalers that supply Canadian mail order pharmacies that sell to American patients. These pharmacies, clustered in Manitoba, take advantage of the price difference between the two countries. Recently, AstraZeneca, an Anglo-Swedish pharmaceutical manufacturer, indicated that it would take similar action. Glaxo has weathered a storm of accusations that it is preventing American patients from getting the company’s medicines at affordable prices.